Matthew Fell, Ph.D. Principal Scientist, Neuroimmunology
Merck Research Laboratories
Matt is currently a Principal Scientist and lab head in the Neuroimmunology group at Merck Research Laboratories in Boston. At Merck, Matt leads a team of drug discovery scientists focused on developing novel treatments for neurodegenerative diseases (including Alzheimer’s disease, ALS and Parkinson’s disease) and he currently co-leads Merck’s LRRK2 kinase inhibitor program for Parkinson’s disease. Prior to joining Merck, Matt received post-doctoral training in the Neuroscience department at Eli Lilly and Company in Indianapolis where his research focused on the therapeutic potential of group II metabotropic glutamate receptors in psychiatric and neurodegenerative disorders. Matt received his Bachelor of Science with Honors in Biomedical Sciences/Pharmacology and a Ph.D degree in Neuropsychopharmacology from the University of Bradford, UK and has published 24 peer reviewed articles.